Category Archives: Market Access

Japan's Schizophrenia Market to Double by 2022, Says Report

Japan’s schizophrenia treatment market value will see revenues doubling from $0.7 billion in 2012 to $1.4 billion by 2022 (a Compound Annual Growth Rate [CAGR] of 7.74%), says a new report from  GlobalData.
Also posted in Global | Tagged , , , | Leave a comment

Obama Administration Halts Attack on Medicare Drug Plans

In an abrupt about-face, the Obama administration halted its ill-timed effort to launch an overhaul of the Medicare Part D program and announced it would not pursue changes in some key rules as proposed earlier this year. CMS had issued a proposed rule January 10 to drop “protected” class status for antidepressants and immunosuppressants in […]
Also posted in FDA, healthcare, Legal | Tagged , , , , , , , | Leave a comment

New Fees Made FDA Worse for Generic Drug Approvals, Says GPhA Chairman

‘Actions’ don’t speak louder than words in dealing with FDA’s backlog of generic drug applications, says newly-elected GPhA Board Chairman Craig Wheeler. When the Generic Drug User Fee Act (GDUFA) was signed into law on July 7, 2012, its primary intent was to provide FDA with the additional resources necessary to expedite the review process […]
Also posted in FDA, Legal, People, R&D, Regulatory, Strategy | Tagged , , , , , , | Leave a comment

Bringing New Rx Drugs to Market in 2014

by Tom Norton I did something today that I haven’t done in years: I checked out the US pharmaceutical R&D spend versus the rest of the world. Having known since the 80’s that the US owned this space, a quick look at the latest R&D figures confirmed my decades old understanding of the industry’s worldwide […]
Also posted in Biotech, Corporate Responsibility, Emerging Markets, Europe, FDA, Global, Guest Blog, pricing, Strategy | Tagged , , , , , , | 3 Comments

Love Potion #9: The Hypoactive Sexual Desire Disorder Pipeline

New products in development for women distressed by a lack of sexual desire and satisfying sexual experiences are causing a stir, but not for the reasons one might expect.   Do women have less of a right than men to combat sexual disorders with pills? That’s the question eight national and international women’s advocacy groups […]
Also posted in FDA, healthcare, leadership, Patient Communication, R&D, Regulatory, Safety, Strategy | Tagged , , , , , , , , , | 1 Comment
  • Categories

  • Meta